Top

Published in:

01-06-2012 | Antiretroviral Therapies (A Pozniak, Section Editor)

HIV Therapies and the Kidney: Some Good, Some Not So Good?

Authors: Lene Ryom, Amanda Mocroft, Jens Lundgren

Published in: Current HIV/AIDS Reports | Issue 2/2012

Abstract

Several observational studies have identified tenofovir as an independent risk factor for kidney impairment. Conversely, randomized trials have only demonstrated minor tenofovir-related changes in kidney function, but these studies included patients with normal kidney function and with low underling risk for progression of their renal function, had limited size, and limited follow-up. Several potential mechanisms of tenofovir nephrotoxicity are known. Atazanavir can, equally to indinavir, cause urolithiasis, but both drugs have also been associated with chronic kidney disease (CKD) and fast declining eGFR in persons without clinical symptoms of urolithiasis, especially when the plasma drug concentration is boosted by concomitant ritonavir use. In 2012, only a minority of HIV-positive individuals are affected by drug-induced nephrotoxicity. However, in the future, the clinical impact and hence the requirement for more research in this area will likely increase due to ageing and continued cART exposure of the HIV-positive population.

Alsauskas ZC, Medapalli RK, Ross MJ. Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients. Expert Opin Pharmacother. 2011;12:691–704.PubMedCrossRef

Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007;21:685–92.PubMedCrossRef

Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22:2409–18.PubMedCrossRef

Moreno-Cuerda VJ, Morales-Conejo M, Rubio R. Antiretroviral treatment associated life-threatening adverse events. Med Clin (Barc). 2006;126:744–9.CrossRef

Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case–control study. J Acquir Immune Defic Syndr. 2004;37:1489–95.PubMedCrossRef

El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.PubMedCrossRef

Neuhaus J, Mocroft A, Wyatt C, Ross M. Predictors of chronic kidney disease: SMART Trial, Poster837. In: CROI. Boston, USA; 2011.

• Barraclough K, Er L, Ng F, et al. A comparison of the predictive performance of different methods of kidney function estimation in a well-characterized HIV-infected population. Nephron Clin Pract. 2009;111:c39–48. Pilot study comparing different methods of evaluating kidney function among 27 HIV-positive individuals. Compared to a nuclear-based assessment, the MDRD equation and 24-hour urine creatinine clearance were most accurate..PubMedCrossRef

Menezes AM, Torelly Jr J, Real L, et al. Prevalence and risk factors associated to chronic kidney disease in HIV-Infected patients on HAART and undetectable viral load in Brazil. PLoS One. 2011;6:e26042.PubMedCrossRef

10.

Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.PubMedCrossRef

11.

Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–96.PubMedCrossRef

12.

Young B, Buchacz K, Baker RK, et al. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic). 2007;6:178–87.CrossRef

13.

Mocroft A. The difficulties of classifying renal disease in HIV-infected patients. HIV Med. 2011;12:1–3.PubMedCrossRef

14.

Schwartz EJ, Szczech LA, Ross MJ, et al. Highly active antiretroviral therapy and the epidemic of HIV+end-stage renal disease. J Am Soc Nephrol. 2005;16:2412–20.PubMedCrossRef

15.

Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57.PubMedCrossRef

16.

Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS. 2009;23:2143–9.PubMedCrossRef

17.

• Campbell LJ, Hamzah L, Post FA. Is tenofovir-related renal toxicity incompletely reversible? J Acquir Immune Defic Syndr. 2011;56:e95. author reply e95-96. A UK study investigating GFR slopes before, during, and after tenofovir initiation. Found that the accelerated eGFR decline seen after tenofovir initiation was largely reversible after tenofovir discontinuation..PubMed

18.

Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS. 2004;18:1074–6.PubMedCrossRef

19.

Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804–17.PubMedCrossRef

20.

Harris M. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Expert Opin Drug Saf. 2008;7:389–400.PubMedCrossRef

21.

Lee JC, Marosok RD. Acute tubular necrosis in a patient receiving tenofovir. AIDS. 2003;17:2543–4.PubMedCrossRef

22.

Szczech LA. Renal dysfunction and tenofovir toxicity in HIV-infected patients. Top HIV Med. 2008;16:122–6.PubMed

23.

Wyatt CM, Klotman PE. Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection. Expert Opin Drug Saf. 2006;5:275–87.PubMedCrossRef

24.

Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med. 1999;340:392–3.PubMedCrossRef

25.

Rodriguez-Novoa S, Alvarez E, Labarga P, et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9:545–59.PubMedCrossRef

26.

Schmid S, Opravil M, Moddel M, et al. Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies. Virchows Arch. 2007;450:665–70.PubMedCrossRef

27.

Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther. 2003;17:265–85.PubMedCrossRef

28.

Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302–9.PubMedCrossRef

29.

Kalyesubula R, Perazella MA. Nephrotoxicity of HAART. AIDS Res Treat. 2011;2011:562790.PubMed

30.

Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis. 2006;42:283–90.PubMedCrossRef

31.

Antoniou T, Raboud J, Chirhin S, et al. Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. 2005;6:284–90.PubMedCrossRef

32.

Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743–6.PubMedCrossRef

33.

Kohler JJ, Hosseini SH, Hoying-Brandt A, et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest. 2009;89:513–9.PubMedCrossRef

34.

Lebrecht D, Venhoff AC, Kirschner J, et al. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr. 2009;51:258–63.PubMedCrossRef

35.

Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331–3.PubMedCrossRef

36.

Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174–6.PubMedCrossRef

37.

Wyatt CM, Winston J. Renal disease in patients with HIV. Curr Infect Dis Rep. 2006;8:76–81.PubMedCrossRef

38.

Irizarry-Alvarado JM, Dwyer JP, Brumble LM, et al. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read. 2009;19:114–21.PubMed

39.

Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–73.PubMed

40.

Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med. 2010;11:308–17.PubMedCrossRef

41.

Morlat P VA, Dauchy F, et al. Antiretroviral drugs and incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort (2004–2008) In: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Edited by WEPDB0104 A. Rome, Italy; 2011.

42.

Heffelfinger J HD, Voetsch A, et al. Renal impairment associated with the use of tenofovir, Poster 779. In: CROI. Denver; 2006.

43.

• Scherzer R MME, Li Y et al. Association of tenofovir exposure with kidney disease risk in HIV-infection. TH-OR064 In: J Am Soc Nephrol. 22; 2011. Large US study identifying tenofovir, but no other ARVs, to be associated with excess risk of proteinuria, rapid progression in eGFR, and eGFR < 60 mL/min.

44.

• Campo R DE, Khanlou H, et al. SWIFT Study: switching from Lamivudine/Abacavir (3TC/ABC) to Emtricitabine/Tenofovir DF (FTC/TDF), Abstract H2-786. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2011. A randomized trial that found that median decline in eGFR for tenofovir-exposed significantly exceeded that of abacavir at week 48. Differs from other trials in that the majority of patients had other co- morbidities.

45.

Rho M, Perazella MA. Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients. Curr Drug Saf. 2007;2:147–54.PubMedCrossRef

46.

Brennan A, Evans D, Maskew M, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25:1603–9.PubMedCrossRef

47.

Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–79.PubMedCrossRef

48.

Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296–7.PubMed

49.

• Flandre P, Pugliese P, Cuzin L, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6:1700–7. New AIDS data. Large prospective cohort study that identified tenofovir, abacavir, and indinavir as independent risk factors for CKD..PubMedCrossRef

50.

Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int. 2005;67:393–403.PubMedCrossRef

51.

Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22:1374–6.PubMedCrossRef

52.

Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25:1671–3.PubMedCrossRef

53.

Knudtson E, Para M, Boswell H, et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003;101:1094–7.PubMedCrossRef

54.

Harris M MH, YIB B, et al. Hyoposphatemia and albuminuria are associated with older age in HIV+adults receiving ART, Abstract P_01. In: 2nd international workshop on HIV and ageing. Baltimore, USA; 2011.

55.

• Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24:1667–78. Large prospective cohort study that identified predictors for CKD including tenofovir, atazanavir, indinavir, and possibly lopinavir/r..PubMedCrossRef

56.

Kopp JB, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis. 2002;34:1122–8.PubMedCrossRef

57.

Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med. 1997;336:138.PubMed

58.

Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705–6.PubMedCrossRef

59.

Feicke A, Rentsch KM, Oertle D, et al. Same patient, new stone composition: amprenavir urinary stone. Antivir Ther. 2008;13:733–4.PubMed

60.

Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol. 2002;167:1384–5.PubMedCrossRef

61.

Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patient taking saquinavir. Int J STD AIDS. 1998;9:555.PubMedCrossRef

62.

Lalezari JP, Henry K, O’Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–85.PubMedCrossRef

63.

Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563–73.PubMedCrossRef

64.

• Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99–103. Review of tenofovir safety data based on the FDA adverse event reporting system. A total of 164 cases of Fanconi syndrome were reported up to 2006. A substantial number of these patients required hospitalization (46%) and 2% died..PubMedCrossRef

65.

Crum-Cianflone N, Ganesan A, Teneza-Mora N, et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010;24:353–60.PubMedCrossRef

66.

Roe J, Campbell LJ, Ibrahim F, et al. HIV care and the incidence of acute renal failure. Clin Infect Dis. 2008;47:242–9.PubMedCrossRef

67.

Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Nephrol Dial Transplant. 1999;14:1578–85.PubMedCrossRef

68.

Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273–81.PubMedCrossRef

69.

Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297–304.PubMedCrossRef

70.

Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab Invest. 2011;91:852–8.PubMedCrossRef

71.

Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469–87.PubMedCrossRef

72.

Cote HC, Magil AB, Harris M, et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther. 2006;11:79–86.PubMed

73.

Cihlar T, Birkus G, Greenwalt DE, et al. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 2002;54:37–45.PubMedCrossRef

74.

Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265–72.PubMedCrossRef

75.

Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257–63.PubMedCrossRef

76.

Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–73.PubMedCrossRef

77.

• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74–8. The 144 weeks results of the GS934 trial. Showed no significant differences in creatinine levels or proteinuria between tenofovir and zidovudine groups, but median eGFR changes were significantly higher among tenofovir exposed estimated by the MDRD equation. Changes occurred in the first 96 weeks. The trial was carried out in a low-risk renal group..PubMedCrossRef

78.

Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J Acquir Immune Defic Syndr. 2010;53:62–9.PubMedCrossRef

79.

Fux C. Tenofovir and PI use are associated with an increased prevalence of proximal renal tubular dysfunction in the Swiss HIV Cohort Study. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections Montréal, Canada.; 2009.

80.

• Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505. Meta-analyses and review of primarily RCTs. Found only a modest effect of tenofovir on renal function during a median follow-up of 48 weeks..PubMedCrossRef

81.

A Avihingsanon KP, J Wongsabut, et al. HIVNAT 006 Study team prevalence and prognostic factors of chronic kidney disease in HIV-infected patients, HIV-NAT 006 Cohort, Thailand, poster 843. In: CROI. Boston; 2011.

82.

Gallant JE, Parish MA, Keruly JC, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–8.PubMedCrossRef

83.

Buchacz K, Brooks JT, Tong T, et al. Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. 2006;7:451–6.PubMedCrossRef

84.

Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191–201.PubMedCrossRef

85.

Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60.PubMedCrossRef

86.

Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008;22:2155–63.PubMedCrossRef

87.

Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 2007;21:1119–27.PubMedCrossRef

88.

Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17:831–40.PubMedCrossRef

89.

Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635–42.PubMedCrossRef

90.

Brewster UC, Perazella MA. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44:e81–4.PubMed

91.

Chang HR, Pella PM. Atazanavir urolithiasis. N Engl J Med. 2006;355:2158–9.PubMedCrossRef

92.

Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191–201.PubMedCrossRef

93.

Albini L, Cesana BM, Motta D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr. 2012;59:18–30.PubMedCrossRef

94.

Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet. 1996;348:693.PubMedCrossRef

95.

Chan-Tack KM, Truffa MM, Struble KA, et al. Atazanavir-associated nephrolithiasis: cases from the US food and drug administration’s adverse event reporting system. AIDS. 2007;21:1215–8.PubMedCrossRef

96.

Reilly RF, Tray K, Perazella MA. Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable risk factors. Am J Kidney Dis. 2001;38:E23.PubMedCrossRef

97.

Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78–81.PubMedCrossRef

98.

Bredeek F GR, Yolo R, Schneider S. A switch from TDF/FTC to raltegravir in patients on a boosted protease inhibitor is effective in reducing proteinuria and increasing GFR, Abstract H1-1399b. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, USA; 2011.

99.

Kowalska JD, Kirk O, Mocroft A, et al. Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. HIV Med. 2010;11:200–8.PubMedCrossRef

100.

Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2005;40:1559–85.PubMedCrossRef

Title: HIV Therapies and the Kidney: Some Good, Some Not So Good?
Authors: Lene Ryom
Amanda Mocroft
Jens Lundgren
Publication date: 01-06-2012
Publisher: Current Science Inc.
Published in: Current HIV/AIDS Reports / Issue 2/2012
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI: https://doi.org/10.1007/s11904-012-0110-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Antiviral Drugs and the Treatment of Hepatitis C

Should We Treat Acute HIV Infection?

HIV-1 Prevention for HIV-1 Serodiscordant Couples

Protease Inhibitor Monotherapy: What Is Its Role?

HIV and Inflammation: Mechanisms and Consequences

Eliminating the HIV Reservoir

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials